CanSino Biologics Inc. (CanSinoBIO) released unaudited results for the six months ended 30 June 2026.
Financial Highlights • Revenue climbed 46.10 % year-on-year to RMB 546.65 million (USD 75.40 million), driven by sustained domestic uptake of Menhycia® (MCV4) and the commercial launch of 13-valent pneumococcal conjugate vaccine iPneucia®. • Overseas business—principally technology transfer fees and intermediate-product shipments—contributed RMB 152.16 million, accounting for 27.83 % of total revenue. • Gross profit increased 39.40 % to RMB 413.47 million, yielding a margin of 75.60 % (1H 2025: 79.30 %). • Operating profit reached RMB 27.54 million versus a RMB 2.21 million loss a year earlier; net loss narrowed sharply to RMB 0.72 million, translating into diluted EPS of RMB 0.00. • Operating cash outflow stood at RMB 119.55 million, while net cash from investing activities amounted to RMB 414.34 million owing to structured-deposit redemptions.
Balance Sheet • Total assets were RMB 6.83 billion, with equity of RMB 4.98 billion. • Cash and cash equivalents totalled RMB 1.17 billion; interest-bearing borrowings fell 24.20 % to RMB 966.50 million, reflecting repayment of short-term loans. • Inventories increased 12.06 % to RMB 379.12 million to support upcoming sales.
Commercial Portfolio and Pipeline • Eight marketed products now include Menhycia®, Menphecia®, iPneucia®, Tripecia®, Tetcia®, Convidecia®, Convidecia Air®, and Ad5-EBOV. • Tripecia® (DT3cP Infant) and Tetcia® (Tetanus Vaccine) both received NMPA approval in April and August 2026, respectively, and have commenced distribution. • MCV4 obtained additional age-expansion clearance (3 months–6 years) and its Argentina drug registration certificate, furthering internationalisation. • Priority review was granted for Td5cp Adolescent and Adult; Phase I/II trials initiated for 24-valent pneumococcal conjugate vaccine (PCV24). • mRNA platform advanced via ISL-3C-LNP delivery system licensing and joint R&D agreements in Malaysia and China.
Capital Deployment • RMB 905.70 million invested to date in the CanSino Innovative Vaccine Industrial Campus; completion expected by end-2026. • Outstanding capital commitments total RMB 17.47 million.
Other Developments • No interim dividend declared. • A Brazilian lawsuit seeking approximately RMB 220 million in damages has been initiated; management, citing legal advice, considers an outflow “not probable” and has made no provision.
Outlook Management will focus on accelerating domestic market penetration of newly launched vaccines, scaling international sales through technology transfer and registrations in Southeast Asia, the Middle East, and Latin America, and advancing first-in-class pipeline candidates to sustain long-term growth.